Estudo randomizado | Risankizumabe como terapia de manutenção para doença de Crohn gravemente ativa.
31 Mai, 2022 | 12:13hRisankizumab as maintenance therapy for moderately to severely active Crohn’s disease: results from the multicentre, randomised, double-blind, placebo-controlled, withdrawal phase 3 FORTIFY maintenance trial – The Lancet (link para o resumo – $ para o texto completo)